| Name | Title | Contact Details |
|---|---|---|
Patrick Phillips |
Chief Operating Officer | Profile |
Mike Lynch |
Executive Director, IT Delivery | Profile |
Matt Edwards |
Sr. Director, IT Operations & Security | Profile |
FOB Synthesis is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
GenVault Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Curis is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.